Search Results

MED-EL, a leader in implantable hearing solutions, celebrates together with everyone living with and benefiting from cochlear implants.

Kane Biotech Inc. announces that it has entered into a worldwide license agreement with I-MED Pharma Inc. (“I-MED Pharma” or “I-MED”) for the DispersinB ® technology.

Telehealth company Henry Meds, known for its commitment to patient-centric care, announced the launch of Compounded Oral Dissolving Tirzepatide Tablets.

ViroCell Biologics announces that John W. Hadden II, Chief Executive Officer, will be presenting at the annual Cell & Gene Meeting on the Med to be held April 9-11 in Rome, Italy.

Ipsen and GENFIT announced full results from the pivotal Phase III ELATIVE® trial, which are being presented in a late-breaking oral session at the American Association for the Study of Liver Diseases and simultaneously published in New England Journal of Medicine.

Big Pharma has finally gotten its arms around something advocates have wanted for a long time: direct-to-consumer sales. Eli Lilly and Pfizer are leading the way.

Ipsen (Euronext: IPN; ADR: IPSEY) and GENFIT (Nasdaq and Euronext: GNFT) today announced full results from the pivotal Phase III ELATIVE® trial, which are being presented in a late-breaking oral session (Abstract #484, Monday, 13 November at 16.45 EST) at the American Association for the Study of Liver Disease (AASLD) and simultaneously published in the New England Journal of Medicine (NEJM).